ClinicalTrials.gg
CompletedNCT02129244Updated Oct 6, 2026Results posted

A Nurse Case Management Intervention to Improve MDR-TB/HIV Co-Infection Outcomes

An interventional study of NCM-Plus in MDR-TB and HIV, sponsored by Johns Hopkins University. Completed at 15 sites in South Africa. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Johns Hopkins University · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 6, 2026Now CompletedResults posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,844
Allocation
Randomized
Ages
13 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Tuberculosis, Multidrug-Resistant with a site in South Africa — 7 open to participants now, 8 under way, 3 of them phase 3. Tuberculosis, Multidrug-Resistant · South Africa.

Enrollment
3rd of 37
2,844 · median 248
Started
2014
with 3 others
No phase
8 of 46
5 open now
Registered
9th of 46
by date
Lead sponsor
2 of 46
Johns Hopkins University

Among the 46 studies in Tuberculosis, Multidrug-Resistant with a site in South Africa, this one is the 3rd largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2014, is one of 8 with no phase, and was the 9th registered.

Tuberculosis, Multidrug-Resistant

132 studies on the registry are indexed under Tuberculosis, Multidrug-Resistant; 25 are open to participants now.

Browse Tuberculosis, Multidrug-Resistant studies →

Open to participants now

7 of the 46 studies in Tuberculosis, Multidrug-Resistant with a site in South Africa are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →

Who these studies take

Of the 20 Tuberculosis, Multidrug-Resistant studies recruiting now, 12 (60%) set no upper age limit and 7 (35%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 13 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Tuberculosis, Multidrug-Resistant with a site in South Africa, or all of them as a file.
02

Study summary

The researchers of this study are observing the treatment of multi-drug resistant Mycobacterium tuberculosis (MDR-TB) in South Africa. MDR-TB can not be treated with the usual TB drugs and needs to be treated with special drugs. The patients need to take these drugs for up to two years. Certain hospitals have already agreed to participate in this research project, half of the hospitals will be assigned a nurse case manager and the other half will not. The researchers are studying the benefits of having a nurse case manager to improve treatment response for patients with drug resistant TB. The researchers believe that nurse case management (NCM) in the intervention sites will increase MDR-TB cure and completion rates (i.e. treatment success) in comparison to usual care (UC), i.e. standardized programmatic management alone, in patients with and without HIV co-infection. To do this, the researchers will review the medical information collected at the hospital as part of the patient's treatment after obtaining the patient's permission.

Read the detailed description

Mycobacterium tuberculosis (TB) remains the leading cause of death among persons living with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) in southern Africa. This syndemic places an overwhelming burden on healthcare workers and the health system. Drug-resistant TB remains a growing threat to public health despite advances in treatment and diagnosis over the past decade. South Africa has the world's highest rate of TB/HIV co-infection and ranks fourth worldwide for both multi-drug resistant (MDR) TB incidence and HIV prevalence. Treatment of MDR-TB, defined as resistance to isoniazid and rifampin, remains challenging and its treatment course complex. Success of second line treatment regimens is considerably less likely than first line treatment with significantly more adverse drug reactions (ADRs). Prospective cohort studies from South Africa report less than 50% treatment success (i.e. cure or completion) and significant differences in patients with and without HIV are noted. Differences in sex and gender as well as age are rarely evaluated. In addition to the management complexity and length of treatment, systems level factors such as access to care and healthcare capacity contribute to poorer treatment outcomes. Insufficient numbers of trained physicians capable and clinically competent to manage the challenges of integrated MDR-TB/HIV care are commonplace. These circumstances place a heavy burden on the most abundant healthcare resource in South Africa, the nurse. Nurses with proficiency in care models for both diseases are essential to improve treatment outcomes. The investigators experience dictates, however, that patients endure lengthy treatment with little assessment, support or guidance from nursing professionals due to a lack of training as well as lack of evidence-based interventions and delineated models of care for MDR-TB patients.

Nurse case management (NCM) models in which a registered nurse facilitates and coordinates treatment plans to ensure that timely, evidence-based care is given improves treatment outcomes. Presently, there is little evidence to describe such models in TB/HIV co-infected patients globally, and specifically less evidence for MDR-TB/HIV in sub-Saharan Africa. Many studies, however, have demonstrated substantial improvements in disease outcomes utilizing nurse case managers. Complex diseases such as heart failure, diabetes, HIV and drug susceptible TB are among these. Substantial gaps remain, however, in the investigators understanding of the impact of such interventions among co-infected patients, the influence of such models among different age groups or the cost-benefit in under resourced settings. Prior studies provide strong evidence that interventions must be multi-faceted and foster system level approaches to improve treatment outcomes (i.e. NCM patient-centered care services coupled with systems level approaches to care coordination). The Chronic Care Model identifies essential elements of a health care system that encourage high-quality chronic disease care in such a systems approach. These elements provide the conceptual model and implementation structure for the proposed NCM plus health systems strengthening (i.e. NCM-plus) intervention, a multi-faceted health systems and patient-centered intervention to improve MDR-TB/HIV treatment outcomes. The proposed 5-year cluster randomized trial, will evaluate the NCM-plus intervention on MDR-TB treatment outcomes in South Africa, the epicenter of the MDR-TB/HIV epidemic.

Primary Aim:

To determine the impact of a NCM model (i.e. NCM-Plus) on MDR-TB outcomes in patients with and without HIV co-infection in South Africa through a cluster randomized trial.

Hypothesis:

Nurse case management (NCM) in intervention sites will increase MDR-TB cure and completion rates (i.e. treatment success) in comparison to usual care (UC), i.e. standardized programmatic management alone, in patients with and without HIV co-infection.

Secondary Aims:

  1. To conduct sub-group analysis by a) HIV co-infection; b) sex and gender; and c) age
  2. To compare the frequency and time to identification of adverse drug events between intervention and control sites.
  3. To conduct a costing analysis and a cost-effectiveness evaluation of the intervention.
03

Conditions studied

  • MDR-TB
  • HIV

Keywords

  • MDR-TB
  • HIV
  • Nurse Case Management (NCM)
04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Center (Cluster Level)

    1. MDR-TB Centers in KwaZulu-Natal (KZN) or Eastern Cape (EC), South Africa providing standardized
    2. MDR-TB regimen according to National Department of Health guidelines
    3. Facility has provided MDR-TB care for a minimum of 6 months at study initiation
    4. MDR-TB Centers with facility-based access to anti-retroviral therapy
    5. Facility willingness to participate in the study
  • Individual (Patient Level)

    1. Patients 18 years of age and older, with microbiologically confirmed MDR- TB, admitted to receive inpatient care at a participating hospital who signs within 7 days of admission.
    2. Patients 13 - 17 years of age, with microbiologically confirmed MDR- TB, who provide consent for study team to contact parent or legal guardian and when patient is willing and parent or legal guardian provides approval for study participation within 7 days of admission.

Exclusion criteria

Exclusion Criteria (Individual Patient Level):

  • Persons who present to the MDR-TB ward who have started MDR-TB treatment prior to admission.
  • Children, less than 13 years of age; only one participating center has an MDR-TB wards for children under 13.
  • Persons who are unable or unwilling to provide for participation
  • Any patient enrolled in another clinical trial that changes standard MDR- TB or care.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,844 participants (actual)

Study arms

  • Active comparator
    NCM Plus Intervention

    The researchers designed the NCM-Plus intervention by integrating the domains of the Chronic Care Model with added attention to linkage to care, building on evidence-based guidelines and the team's pilot findings. In the NCM bundle, the researchers provide extensive details on both proximal and distal outcome variables. Nurse case managers will be hired and trained to improve disease management for patients with MDR-TB and HIV. Specific measurable responsibilities will be implemented by each NCM at sites randomized to receive the intervention. The NCM-patient interaction will occur at the MDR-TB treatment inpatient or outpatient facility.

    Other: NCM-Plus

  • No intervention
    Standard/Usual Care

    Usual care is defined as standardized programmatic management of MDR-TB/HIV without care coordination. Nurses are present as part of the team, but with no special coordination role, leaving the MDR-TB physician solely responsible for treatment outcomes with little support. Physicians see patients weekly during the intensive phase and the patient receives basic daily nursing care without coordination of care, active monitoring of Adverse Drug Reactions (ADR)s or HIV care integration. This care transitions to monthly visits with the physician in the continuation phase, again with very little nursing involvement in care coordination.

Interventions

  • OtherNCM-Plus

    The NCM will follow the domains of the chronic care model by: 1. Assuring effective, efficient clinical care and self-management support 2. Promoting clinical care consistent with scientific evidence and patient preferences 3. Organizing data to facilitate efficient, effective care 4. Empowering and preparing patients to manage their health and health-care needs 5. Mobilizing community resources to meet the needs of patients

06

What researchers measure

Primary outcomes

  1. Patients Who Experience Successful Treatment Outcomes

    Patients who experience successful treatment outcomes

    Time frame: 36 months

Secondary outcomes

  1. Patients Who Experience Successful Treatment Outcomes Based on HIV Co-infection

    Multivariate Analysis using binomial or Poisson-based GEE models

    Time frame: 36 months

  2. Patients Who Experience Successful Treatment Outcomes Based on Sex and Gender

    Multivariate Analysis using binomial or Poisson-based GEE models

    Time frame: 36 months

  3. Patients Who Experience Successful Treatment Outcomes Based on Age

    Multivariate Analysis using binomial or Poisson-based GEE models

    Time frame: 36 months

07

Results

Posted Oct 6, 2026

Participant flow

Recruitment took place from October 2014 - September 2019 in 10 MDR- TB hospitals, 6 were in KwaZulu-Natal in the districts of eThekwini, Ugu, uMgungundlovu, uMkhanyakude, and Harry Gwala. The remaining 4 were in the Eastern Cape in the districts of Nelson Mandela, Sara Baartman, and Buffalo City.

Participant flow — Overall Study
MilestoneStandard/Usual CareNCM Plus Intervention
Started13891455
Completed10411093
Not completed348362
Withdrew: Baseline dst result pre-xdr/xdr152225
Withdrew: Baseline dst result ds-tb2756
Withdrew: Inha/katg mutation34
Withdrew: Transferred out to another facility13059
Withdrew: Withdrawal for any other reason3618

Outcome measures

PrimaryPatients Who Experience Successful Treatment Outcomes

Patients who experience successful treatment outcomes

Time frame:
36 months
Reported as:
Count of participants · Participants
Patients Who Experience Successful Treatment Outcomes
ParticipantsStandard/Usual CareNCM Plus Intervention
Patients Who Experience Successful Treatment Outcomes645706
SecondaryPatients Who Experience Successful Treatment Outcomes Based on HIV Co-infection

Multivariate Analysis using binomial or Poisson-based GEE models

Time frame:
36 months
Reported as:
Count of participants · Participants
Patients Who Experience Successful Treatment Outcomes Based on HIV Co-infection
ParticipantsStandard/Usual CareNCM Plus Intervention
Patients Who Experience Successful Treatment Outcomes Based on HIV Co-infection459531
SecondaryPatients Who Experience Successful Treatment Outcomes Based on Sex and Gender

Multivariate Analysis using binomial or Poisson-based GEE models

Time frame:
36 months
Reported as:
Count of participants · Participants
Patients Who Experience Successful Treatment Outcomes Based on Sex and Gender
ParticipantsStandard/Usual CareNCM Plus Intervention
Male353401
Female292305
SecondaryPatients Who Experience Successful Treatment Outcomes Based on Age

Multivariate Analysis using binomial or Poisson-based GEE models

Time frame:
36 months
Reported as:
Count of participants · Participants
Patients Who Experience Successful Treatment Outcomes Based on Age
ParticipantsStandard/Usual CareNCM Plus Intervention
18 -2410692
25 - 34219223
35 - 44178213
45 - 5498115
55 - 643550
65 - 7489
75 - 8412
85 - 9402

Adverse events

Collected over Enrollment to Treatment Completion, up to 24 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Standard/Usual Care136/1,389 (9.8%)136/1,389 (9.8%)0/1,389 (0%)
NCM Plus Intervention156/1,455 (10.7%)156/1,455 (10.7%)0/1,455 (0%)
Most frequent serious events
Most frequent serious events
EventStandard/Usual CareNCM Plus Intervention
DeathGeneral disorders136/1389156/1455

Baseline characteristics

Participants with data collected

Age, Continuous
Age, Continuous(Years)Standard/Usual CareNCM Plus InterventionTotal
Mean36.5 ± 12.038.2 ± 12.437.4 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)Standard/Usual CareNCM Plus InterventionTotal
Female463435898
Male5786581236
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Standard/Usual CareNCM Plus InterventionTotal
Count of participants——0
Residential Area
Residential Area(Participants)Standard/Usual CareNCM Plus InterventionTotal
City/CBD/Suburb305080
Farm51520
Township225540765
Rural Village7764791255
Unknown5914
Housing Type
Housing Type(Participants)Standard/Usual CareNCM Plus InterventionTotal
House9219541875
Flat262753
Informal/Shack6496160
Homeless/Other301646
Highest Level of Education
Highest Level of Education(Participants)Standard/Usual CareNCM Plus InterventionTotal
None/Less than Secondary7717901561
Secondary School197218415
Some Technical/College Training304575
Technical/College Completed434083
Employment Status
Employment Status(Participants)Standard/Usual CareNCM Plus InterventionTotal
Employed288373661
Student8359142
Unemployed6356151250
Retired/Disabled323769
Unknown3912
Marital Status
Marital Status(Participants)Standard/Usual CareNCM Plus InterventionTotal
Married104148252
Partnered/In a Relationship354182536
Separated/Widowed673097
Single5107221232
Unknown61117

21 further baseline measures are reported on the registry.

08

Study locations

15 sites
  • Regus Primary Office
    Westville, Durban 3629, South Africa
  • Catherine Booth Hospital
    aMatikulu, KwaZulu-Natal, South Africa
  • Don McKenzie
    Durban, South Africa
  • King George V Hospital
    Durban, South Africa
  • Fort Gray Hospital
    East London, South Africa
  • Dunstan Farrell Hospital
    Hibberdene, South Africa
  • Hlabisa Hospital
    Hlabisa, South Africa
  • Manguzi
    Manguzi, South Africa
  • Nkqubela
    Mdantsane, South Africa
  • Fosa Hospital
    Newlands West, South Africa
  • Doris Goodwin Hospital
    Pietermaritzburg, South Africa
  • Marjorie Parrish Hospital
    Port Alfred, South Africa
  • Jose Pearson Hospital
    Port Elizabeth, South Africa
  • Murchison Hospital
    Port Shepstone, South Africa
  • St Margaret's MDR-TB Hopsital
    Umzimkulu, South Africa
09

References and documents

Publications

  • World Health Organization. Global Tuberculosis Control. WHO/HTM/TB/2010.7. 2010. Geneva, Switzerland.
  • World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. [WHO/HTM/TB/2010.3]. 2010. World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland, WHO Press.
  • Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, Gandhi NR, Galvani AP. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009 Mar;9(3):153-61. doi: 10.1016/S1473-3099(09)70041-6. PubMed 19246019 ↗
  • Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One. 2009 Sep 9;4(9):e6914. doi: 10.1371/journal.pone.0006914. PubMed 19742330 ↗
  • Farley JE, Ram M, Pan W, Waldman S, Cassell GH, Chaisson RE, Weyer K, Lancaster J, Van der Walt M. Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence. PLoS One. 2011;6(7):e20436. doi: 10.1371/journal.pone.0020436. Epub 2011 Jul 22. PubMed 21799728 ↗
  • Shean KP, Willcox PA, Siwendu SN, Laserson KF, Gross L, Kammerer S, Wells CD, Holtz TH. Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992-2002. Int J Tuberc Lung Dis. 2008 Oct;12(10):1182-9. PubMed 18812049 ↗
  • Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, Scott M, Weissman D, Marra C, Lalloo UG, Friedland GH; Tugela Ferry Care and Research (TF CARES) Collaboration. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med. 2010 Jan 1;181(1):80-6. doi: 10.1164/rccm.200907-0989OC. Epub 2009 Oct 15. PubMed 19833824 ↗
  • Somma D, Thomas BE, Karim F, Kemp J, Arias N, Auer C, Gosoniu GD, Abouihia A, Weiss MG. Gender and socio-cultural determinants of TB-related stigma in Bangladesh, India, Malawi and Colombia. Int J Tuberc Lung Dis. 2008 Jul;12(7):856-66. PubMed 18544216 ↗
  • O'Donnell MR, Zelnick J, Werner L, Master I, Loveday M, Horsburgh CR, Padayatchi N. Extensively drug-resistant tuberculosis in women, KwaZulu-Natal, South Africa. Emerg Infect Dis. 2011 Oct;17(10):1942-5. doi: 10.3201/eid1710.110105. PubMed 22000378 ↗
  • Vella V, Racalbuto V, Guerra R, Marra C, Moll A, Mhlanga Z, Maluleke M, Mhlope H, Margot B, Friedland G, Shah NS, Gandhi NR. Household contact investigation of multidrug-resistant and extensively drug-resistant tuberculosis in a high HIV prevalence setting. Int J Tuberc Lung Dis. 2011 Sep;15(9):1170-5, i. doi: 10.5588/ijtld.10.0781. PubMed 21943840 ↗
  • National Department of Health, South Africa. Decentralized Management of Multi-Drug Resistant Tuberculosis: A Policy Framework for South Africa. 2011.
  • Welch G, Garb J, Zagarins S, Lendel I, Gabbay RA. Nurse diabetes case management interventions and blood glucose control: results of a meta-analysis. Diabetes Res Clin Pract. 2010 Apr;88(1):1-6. doi: 10.1016/j.diabres.2009.12.026. Epub 2010 Feb 8. PubMed 20116879 ↗
  • Nyamathi A, Nahid P, Berg J, Burrage J, Christiani A, Aqtash S, Morisky D, Leake B. Efficacy of nurse case-managed intervention for latent tuberculosis among homeless subsamples. Nurs Res. 2008 Jan-Feb;57(1):33-9. doi: 10.1097/01.NNR.0000280660.26879.38. PubMed 18091290 ↗
  • Del Sindaco D, Pulignano G, Minardi G, Apostoli A, Guerrieri L, Rotoloni M, Petri G, Fabrizi L, Caroselli A, Venusti R, Chiantera A, Giulivi A, Giovannini E, Leggio F. Two-year outcome of a prospective, controlled study of a disease management programme for elderly patients with heart failure. J Cardiovasc Med (Hagerstown). 2007 May;8(5):324-9. doi: 10.2459/JCM.0b013e32801164cb. PubMed 17443097 ↗
  • Anaya HD, Hoang T, Golden JF, Goetz MB, Gifford A, Bowman C, Osborn T, Owens DK, Sanders GD, Asch SM. Improving HIV screening and receipt of results by nurse-initiated streamlined counseling and rapid testing. J Gen Intern Med. 2008 Jun;23(6):800-7. doi: 10.1007/s11606-008-0617-x. Epub 2008 Apr 18. PubMed 18421508 ↗
  • Andersen MD, Smereck GA, Hockman EM, Ross DJ, Ground KJ. Nurses decrease barriers to health care by "hyperlinking" multiple-diagnosed women living with HIV/AIDS into care. J Assoc Nurses AIDS Care. 1999 Mar-Apr;10(2):55-65. doi: 10.1016/S1055-3290(06)60299-9. PubMed 10065410 ↗
  • Schumann A, Nyamathi A, Stein JA. HIV risk reduction in a nurse case-managed TB and HIV intervention among homeless adults. J Health Psychol. 2007 Sep;12(5):833-43. doi: 10.1177/1359105307080618. PubMed 17855466 ↗
  • Nyamathi AM, Christiani A, Nahid P, Gregerson P, Leake B. A randomized controlled trial of two treatment programs for homeless adults with latent tuberculosis infection. Int J Tuberc Lung Dis. 2006 Jul;10(7):775-82. PubMed 16848340 ↗
  • Hsieh CJ, Lin LC, Kuo BI, Chiang CH, Su WJ, Shih JF. Exploring the efficacy of a case management model using DOTS in the adherence of patients with pulmonary tuberculosis. J Clin Nurs. 2008 Apr;17(7):869-75. doi: 10.1111/j.1365-2702.2006.01924.x. PubMed 17850292 ↗
  • Wagner EH, Glasgow RE, Davis C, Bonomi AE, Provost L, McCulloch D, Carver P, Sixta C. Quality improvement in chronic illness care: a collaborative approach. Jt Comm J Qual Improv. 2001 Feb;27(2):63-80. doi: 10.1016/s1070-3241(01)27007-2. PubMed 11221012 ↗
  • Wagner EH, Bennett SM, Austin BT, Greene SM, Schaefer JK, Vonkorff M. Finding common ground: patient-centeredness and evidence-based chronic illness care. J Altern Complement Med. 2005;11 Suppl 1:S7-15. doi: 10.1089/acm.2005.11.s-7. PubMed 16332190 ↗
  • Institute of Medicine (US) Committee on Envisioning a Strategy for the Long-Term Burden of HIV/AIDS: African Needs and U.S. Interests. Preparing for the Future of HIV/AIDS in Africa: A Shared Responsibility. Washington (DC): National Academies Press (US); 2011. Available from http://www.ncbi.nlm.nih.gov/books/NBK209740/ PubMed 24983048 ↗
  • Joint United Nations Programme on HIV/AIDS (UNAIDS). Global Report: UNAIDS Report on the Global AIDS Epidemic, 2010. UNAIDS/10.11E | JC1958E. 2010.
  • National Department of Health, South Africa. Decentalized Management of Multi-Drug Resistant Tuberculosis: A Policy Framework for South Africa. 2010.
  • Department of Labour. The shortage of Medical Doctors in South Africa: Scarce and critical skills research project. 1-30-2009.
  • National Department of Health, South Africa. Programmatic Management of Multi-Drug Resistant Tuberculosis: Emergency Update. 2008.
  • Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, Zarovska E, Rich ML, Fraser HS, Alarcon E, Cegielski JP, Grzemska M, Gupta R, Espinal M. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005 Jun;9(6):640-5. PubMed 15971391 ↗
  • Brust JC, Gandhi NR, Carrara H, Osburn G, Padayatchi N. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003. Int J Tuberc Lung Dis. 2010 Apr;14(4):413-9. PubMed 20202298 ↗
  • Lin RL, Lin FJ, Wu CL, Peng MJ, Chen PJ, Kuo HT. Effect of a hospital-based case management approach on treatment outcome of patients with tuberculosis. J Formos Med Assoc. 2006 Aug;105(8):636-44. doi: 10.1016/S0929-6646(09)60162-5. PubMed 16935764 ↗
  • Nathanson E, Nunn P, Uplekar M, Floyd K, Jaramillo E, Lonnroth K, Weil D, Raviglione M. MDR tuberculosis--critical steps for prevention and control. N Engl J Med. 2010 Sep 9;363(11):1050-8. doi: 10.1056/NEJMra0908076. No abstract available. PubMed 20825317 ↗
  • Department of Health. Management of Drug Resistant Tuberculosis: Policy Guidelines. i-151. 8-1-2012.
  • Department of Health. National Strategic Plan on HIV, STIs and TB (2012-2016). 1-78. 12-1-2012.
  • Boulle A, Clayden P, Cohen K, Cohen T, Conradie F, Dong K, Geffen N, Grimwood A, Hurtado R, Kenyon C, Lawn S, Maartens G, Meintjes G, Mendelson M, Murray M, Rangaka M, Sanne I, Spencer D, Taljaard J, Variava E, Venter WD, Wilson D. Prolonged deferral of antiretroviral therapy in the SAPIT trial: did we need a clinical trial to tell us that this would increase mortality? S Afr Med J. 2010 Sep 7;100(9):566, 568, 570-1. doi: 10.7196/samj.4434. No abstract available. PubMed 20822639 ↗
  • Dheda K, Lampe FC, Johnson MA, Lipman MC. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis. 2004 Nov 1;190(9):1670-6. doi: 10.1086/424676. Epub 2004 Sep 29. PubMed 15478074 ↗
  • National Department of Health, South Africa. The South African Antiretroviral Treatement Guidelines 2010. 2010. 2010.
  • Iseman MD. Treatment and implications of multidrug-resistant tuberculosis for the 21st century. Chemotherapy. 1999;45 Suppl 2:34-40. doi: 10.1159/000048480. PubMed 10449896 ↗
  • Weyer K, Brand J, Lancaster J, Levin J, van der Walt M. Determinants of multidrug-resistant tuberculosis in South Africa: results from a national survey. S Afr Med J. 2007 Nov;97(11 Pt 3):1120-8. No abstract available. PubMed 18250922 ↗
  • Amuha MG, Kutyabami P, Kitutu FE, Odoi-Adome R, Kalyango JN. Non-adherence to anti-TB drugs among TB/HIV co-infected patients in Mbarara Hospital Uganda: prevalence and associated factors. Afr Health Sci. 2009 Aug 1;9 Suppl 1(Suppl 1):S8-15. PubMed 20589161 ↗
  • Swaminathan S, Narendran G, Venkatesan P, Iliayas S, Santhanakrishnan R, Menon PA, Padmapriyadarsini C, Ramachandran R, Chinnaiyan P, Suhadev M, Sakthivel R, Narayanan PR. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. Am J Respir Crit Care Med. 2010 Apr 1;181(7):743-51. doi: 10.1164/rccm.200903-0439OC. Epub 2009 Dec 3. PubMed 19965813 ↗
  • Cramm JM, Finkenflugel HJ, Moller V, Nieboer AP. TB treatment initiation and adherence in a South African community influenced more by perceptions than by knowledge of tuberculosis. BMC Public Health. 2010 Feb 17;10:72. doi: 10.1186/1471-2458-10-72. PubMed 20163702 ↗
  • Kliiman K, Altraja A. Predictors and mortality associated with treatment default in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2010 Apr;14(4):454-63. PubMed 20202304 ↗
  • Holtz TH, Lancaster J, Laserson KF, Wells CD, Thorpe L, Weyer K. Risk factors associated with default from multidrug-resistant tuberculosis treatment, South Africa, 1999-2001. Int J Tuberc Lung Dis. 2006 Jun;10(6):649-55. PubMed 16776452 ↗
  • Gardam M, Verma G, Campbell A, Wang J, Khan K. Impact of the patient-provider relationship on the survival of foreign born outpatients with tuberculosis. J Immigr Minor Health. 2009 Dec;11(6):437-45. doi: 10.1007/s10903-008-9221-8. Epub 2009 Jan 6. PubMed 19127431 ↗
  • Bloss E, Kuksa L, Holtz TH, Riekstina V, Skripconoka V, Kammerer S, Leimane V. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004. Int J Tuberc Lung Dis. 2010 Mar;14(3):275-81. PubMed 20132617 ↗
  • National Department of Health, South Africa. Decentralized Management of Multi-Drug Resistant Tuberculosis: A Policy Framework for South Africa (Draft). 2010.
  • World Health Organization. Guidelines for the Programmatic Management of Drug Resistant Tuberculosis; Emergency Update, 2008. WHO/HTM/TB/2008.402. 2008.
  • Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: 2011 Update. Geneva: World Health Organization; 2011. Available from http://www.ncbi.nlm.nih.gov/books/NBK148644/ PubMed 23844450 ↗
  • Wagner EH, Austin BT, Davis C, Hindmarsh M, Schaefer J, Bonomi A. Improving chronic illness care: translating evidence into action. Health Aff (Millwood). 2001 Nov-Dec;20(6):64-78. doi: 10.1377/hlthaff.20.6.64. PubMed 11816692 ↗
  • Moulton LH. Covariate-based constrained randomization of group-randomized trials. Clin Trials. 2004;1(3):297-305. doi: 10.1191/1740774504cn024oa. PubMed 16279255 ↗
  • Institute of Healthcare Improvement. Improving HIV Care: A Modular Quality Improvement Curriculum. Institue of Healthcare Improvemnet . 6-15-2011.
  • Farley JE, Alwood K, Davis JG, Stellenberg E, and van der Walt M. Development and Pilot Testing of MDR-TB/HIV In-Service Training in Rural KwaZulu Natal. National Education Association and Foundation of Nursing University Deans of South Africa Annual Conference . 10-15-2010.
  • Farley JE, Tudor C, Mphahlele M, Franz K, Perrin NA, Dorman S, Van der Walt M. A national infection control evaluation of drug-resistant tuberculosis hospitals in South Africa. Int J Tuberc Lung Dis. 2012 Jan;16(1):82-9. doi: 10.5588/ijtld.10.0791. PubMed 22236851 ↗
  • Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009 Apr;42(2):377-81. doi: 10.1016/j.jbi.2008.08.010. Epub 2008 Sep 30. PubMed 18929686 ↗
  • Roberts C, Roberts SA. Design and analysis of clinical trials with clustering effects due to treatment. Clin Trials. 2005;2(2):152-62. doi: 10.1191/1740774505cn076oa. PubMed 16279137 ↗
  • Campbell MK, Fayers PM, Grimshaw JM. Determinants of the intracluster correlation coefficient in cluster randomized trials: the case of implementation research. Clin Trials. 2005;2(2):99-107. doi: 10.1191/1740774505cn071oa. PubMed 16279131 ↗
  • Campbell MK, Mollison J, Grimshaw JM. Cluster trials in implementation research: estimation of intracluster correlation coefficients and sample size. Stat Med. 2001 Feb 15;20(3):391-9. doi: 10.1002/1097-0258(20010215)20:33.0.co;2-z. PubMed 11180309 ↗
  • Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986 Mar;42(1):121-30. PubMed 3719049 ↗
  • Gallop R, Small DS, Lin JY, Elliott MR, Joffe M, Ten Have TR. Mediation analysis with principal stratification. Stat Med. 2009 Mar 30;28(7):1108-30. doi: 10.1002/sim.3533. PubMed 19184975 ↗
  • Dumas JE, Lynch AM, Laughlin JE, Phillips Smith E, Prinz RJ. Promoting intervention fidelity. Conceptual issues, methods, and preliminary results from the EARLY ALLIANCE prevention trial. Am J Prev Med. 2001 Jan;20(1 Suppl):38-47. doi: 10.1016/s0749-3797(00)00272-5. PubMed 11146259 ↗
  • McNabb KC, Bergman AJ, Patil A, Lowensen K, Mthimkhulu N, Budhathoki C, Perrin N, Farley JE. Travel distance to rifampicin-resistant tuberculosis treatment and its impact on loss to follow-up: the importance of continued RR-TB treatment decentralization in South Africa. BMC Public Health. 2024 Feb 23;24(1):578. doi: 10.1186/s12889-024-17924-0. PubMed 38389038 ↗
  • Geiger K, Patil A, Bergman A, Budhathoki C, Heidari O, Lowensen K, Mthimkhulu N, McNabb KC, Mmed NN, Ngozo J, Reynolds N, Farley JE. Exploring HIV disease indicators at MDR-TB treatment initiation in South Africa. Int J Tuberc Lung Dis. 2024 Jan 1;28(1):42-50. doi: 10.5588/ijtld.23.0242. PubMed 38178293 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Oct 2014 to primary completion in Mar 2021, 77 months.

Results were first posted in Oct 2026, 5 years 7 months after primary completion.

Completion moved once since we started tracking on Sep 25, 2026: Jul 2026 → Dec 2025, on Oct 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2014
First posted
May 2, 2014
StartActual
Oct 2014
Primary completionActual
Mar 2021
CompletionActual
Dec 2025was Jul 2026
Results first posted
Oct 6, 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 6, 2026
Results
Results posted
posted Oct 6, 2026
Study completion
Jul 2026→Dec 2025 (actual)
Oct 6, 2026
Enrollment
3600 (estimated)→2844 (actual)
Oct 6, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedProportion of patients who experience successful treatment outcomesPatients Who Experience Successful Treatment OutcomesTime frame: 24-36 months → 36 months
Oct 6, 2026
Secondary outcomes
3 edited
What changed in the outcomes
  • EditedProportion of patients who experience successful treatment outcomes basedPatients Who Experience Successful Treatment Outcomes Based on HIV coCo-infectionTime frame: 24 to 36 months → 36 months
  • EditedProportion of patients who experience successful treatment outcomes basedPatients Who Experience Successful Treatment Outcomes Based on sexSex and genderGenderTime frame: 24-36 months → 36 months
  • EditedProportion of patients who experience successful treatment outcomes basedPatients Who Experience Successful Treatment Outcomes Based on ageAgeTime frame: 24-36 months → 36 months
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Active, not recruiting→Completed
    Results posted
    Study completion Jul 2026→Dec 2025 (now actual)
    Enrollment 3600 (estimated)→2844 (actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedProportion of patients who experience successful treatment outcomesPatients Who Experience Successful Treatment OutcomesTime frame: 24-36 months → 36 months
    Secondary outcomes 3 edited
    What changed in the outcomes
    • EditedProportion of patients who experience successful treatment outcomes basedPatients Who Experience Successful Treatment Outcomes Based on HIV coCo-infectionTime frame: 24 to 36 months → 36 months
    • EditedProportion of patients who experience successful treatment outcomes basedPatients Who Experience Successful Treatment Outcomes Based on sexSex and genderGenderTime frame: 24-36 months → 36 months
    • EditedProportion of patients who experience successful treatment outcomes basedPatients Who Experience Successful Treatment Outcomes Based on ageAgeTime frame: 24-36 months → 36 months
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02129244
Responsible party
Sponsor
First posted
May 2, 2014
Start date
Oct 2014
Primary completion
Mar 2021
Completion
Dec 2025
Results posted
Oct 6, 2026
Last update
Oct 6, 2026

Study contacts

Jason E Farley, PhD, MPH, NP
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion